Live Breaking News & Updates on Participants With Recurrent

Stay updated with breaking news from Participants with recurrent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer

Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population. ....

Matthew Powell , Hesham Abdullah , Tesaro Inc , Participants With Recurrent , Primary Advanced Endometrial Cancer , Gynecologic Oncology , Washington University School , Dostarlimab Combination , Primary Advanced , Recurrent Endometrial Cancer Pharmacy ,

Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer

In the RUBY phase 3 trial, dostarlimab (Jemperli; GSK) with niraparib (Zejula; GSK) had significant progression free survival compared to the standard of care. ....

Dostarlimab Jemperli , Hesham Abdullah , National Library Of Medicine , Society Of Gynecologic Oncology , Tesaro Inc , Design Cells , Gynecologic Oncology , National Library , United State , Participants With Recurrent , Primary Advanced Endometrial ,